29 Il libro bianco sulle bronchiectasie 1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65(Suppl 1):i1–i58. 2. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017. 3. Chalmers JD, Aliberti S, Filonenko A, et al. Characterisation of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410-1420. doi:10.1164/ rccm.201711-2202OC. 4. Shoemark A, Cant E, Carreto L, et al. Topographical distribution of bronchiectasis and clinical impact. Respir Med. 2021;178:106309. doi:10.1016/j.rmed.2021.106309. 5. Martínez-García MÁ, Maíz L, Olveira C, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):79-87. doi:10.1016/j.arbres.2017.07.015. 6. Hurst JR, Elborn JS, De Soyza A. COPD and bronchiectasis: convergence of two chronic, progressive, disabling diseases. Lancet Respir Med. 2015;3(3):e15–e16. doi:10.1016/S22132600(15)00031-5. 7. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and course of bronchiectasis in patients with α1-antitrypsin deficiency. Respir Med. 2020;164:105922. doi:10.1016/j. rmed.2020.105922. 8. Aliberti S, Goeminne PC, O’Donnell AE, et al. Criteria for the definition of bronchiectasis exacerbations: international consensus. Eur Respir J. 2017;49(6):1700051. doi:10.1183/13993003.000512017. 9. Ringshausen FC, de Roux A, Diel R, et al. Bronchiectasis: A comprehensive review of the concept, pathogenesis, and management. Respir Med. 2013;107(9):1301-1313. doi:10.1016/j. rmed.2013.06.002. 10. Hill AT, Welham SA, Lonergan M, et al. Primary care management of adults with bronchiectasis: a narrative review. Br J Gen Pract. 2020;70(695):e234–e243. doi:10.3399/bjgp20X708149. Bibliografia CAPITOLO 3
RkJQdWJsaXNoZXIy MjQ4NzI=